Home > Insider Trading > Filing (0000950170-23-047311)

Filing Details

Accession Number:: 0000950170-23-047311
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-08 16:57:59
Reporting Period:: 2023-08-23

Accepted Time:: 2023-09-08 16:57:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1880438	An2 Therapeutics Inc.	ANTX	Pharmaceutical Preparations (2834)	820606654

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1914847	Kabeer Aziz	C/O An2 Therapeutics, Inc. 1800 El Camino Real, Suite D Menlo Park CA 94027		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-09-06	3,164	$16.02	2,180,724	No	4	S	Indirect	By Adjuvant Global Health Technology Fund, L.P.
Common Stock	Disposition	2023-09-06	598	$16.02	412,494	No	4	S	Indirect	By Adjuvant Global Health Technology Fund DE, L.P.
Common Stock	Disposition	2023-09-07	2,841	$16.05	2,177,883	No	4	S	Indirect	By Adjuvant Global Health Technology Fund, L.P.
Common Stock	Disposition	2023-09-07	537	$16.05	411,957	No	4	S	Indirect	By Adjuvant Global Health Technology Fund DE, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Adjuvant Global Health Technology Fund, L.P.
No	4	S	Indirect	By Adjuvant Global Health Technology Fund DE, L.P.
No	4	S	Indirect	By Adjuvant Global Health Technology Fund, L.P.
No	4	S	Indirect	By Adjuvant Global Health Technology Fund DE, L.P.

Footnotes

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.